Hints and tips:
...In the field of cardiovascular medicine, for instance, Novartis has a mass of data drawn, over the past decade, from trials involving 100,000 patients....
...Apple is using its Watch to improve fitness and cardiovascular health....
...“People have been working on this for 15 years — I’m amazed what kind of results came out of this competition in three months,” said Andrew Arai, chief of advanced cardiovascular imaging at the National...
...Domain and Rusnano plan eventually to work together with 20 US life science companies to promote the development of drugs to treat viral infections, cardiovascular disease and cancer....
...Bernstein Research, which highlighted the findings in a note issued on Monday, said they showed share performance had a greater statistical effect on heart attacks than cardiovascular drugs released in recent...
...Edwards LifeSciences tumbled after the administrator of the government’s Medicare and Medicaid programmes dealt a blow to hopes of a rapid roll-out for its new cardiovascular device....
...Last year AstraZeneca paid $15.6bn for MedImmune the US drugs specialist in cardiovascular treatment....
...It came as AstraZeneca brought forward its first-quarter results, showing earnings per share up 14 per cent to 89 cents, and formally discontinued its investment in AGI-1067, an experimental late-stage cardiovascular...
...Lidco rose 13.4 per cent to 27.5p after an independent trial indicated its cardiovascular monitoring technology could save an average of £4,000 per patient, equating to a saving of £500m per year for the...
International Edition